Drug manufacturers and hospitals “will likely continue to test the bounds” of the 340B program until Congress passes legislation addressing multiple concerns about it, a University of Southern California (USC) health policy research fellow says in a new white paper.
USC Schaeffer Center for Health Policy & Economics Karen Mulligan says those concerns include 340B duplicate discounts, drug diversion, contract pharmacy, disproportionate share (DSH) hospital eligibility, uncertainty about how hospitals use program savings, and the U.S. Health Resources and Services Administration’s (HRSA) lack of regulatory authority over 340B, all amplified by the program’s “dramatic growth.”
Drug manufacturers and hospitals “will likely continue to test the bounds” of the 340B program until Congress passes legislation addressing multiple concerns about it, a University of Southern California (USC) health policy research fellow says in a new white paper.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
